TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

TCR2 Therapeutics

13/05/2021 17:15

* TCR2 Therapeutics Inc  TCRR.OQ  reported a quarterly adjusted
loss of 58 cents​​ per share for the quarter ended in March. The
mean expectation of nine analysts for the quarter was for a loss
of 53 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* TCR2 Therapeutics Inc's reported EPS for the quarter was a
loss of 58 cents​.
* The mean earnings estimate of analysts had risen by about 5.5%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* TCR2 Therapeutics Inc shares had fallen by 12.6% this
quarter and lost 37.6% so far this year.
* The company reported a quarterly loss of $21.51 million.
* Wall Street's median 12-month price target for TCR2
Therapeutics Inc is $42.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 13 at 04:15 p.m. GMT.
​All figures in US dollars